Ipsen buys an option to Acquire Canbex

Ipsen_Canbex

Canbex, a spin-off of University College London (UCL) that raised a Series A financing of €2.8M in 2013 from MS Ventures, may become part of Ipsen. The French giant payed €6M upfront for the option to purchase 100% of Canbex shares upon completion of the Phase IIa study of Canbex’s lead candidate for the treatment of spasticity in people with multiple sclerosis (MS).

The candidate, known as VSN16R is a novel, orally active small molecule compound intended for the treatment of spasticity in MS and other disorders. Preclinical and Phase I clinical studies have demonstrated that VSN16R has the potential to provide substantially better patient care than existing systemic anti-spastic treatments. Spasticity is a debilitating and painful symptom of MS that consists of involuntary spasms of limbs and torso musculature. With VSN16R, Canbex aims to set a new standard in the treatment of spasticity, and to improve the lives of people worldwide with this serious and incurable disorder.

Marc de Garidel, Chairman and Chief Executive Officer of Ipsen stated: “Ipsen is delighted to enter into a partnership with the UK biotech company Canbex. Their lead compound has demonstrated excellent safety, efficacy and tolerability to date and fits well within our neurology franchise. Indeed, it could be a valuable companion product to Dysport in the treatment of spasticity. The agreement with Canbex also reflects our ambition to maintain our business development efforts to complement organic growth.

Under the financial terms of the agreement, if Ipsen elects to exercise its option to acquire Canbex at the end of the proof of concept Phase IIa study, Canbex’s shareholders will be eligible to receive a total of up to an additional €90M, comprising an acquisition payment, and additional milestone payments contingent upon launch subsequent to achievement of clinical and regulatory success. In addition, Canbex shareholders will be eligible to receive royalties on world-wide annual net sales of VSN16R.

ADVERTISEMENT

Previous post

Cellectis is preparing its IPO in the U.S

Next post

Unstoppable Ferring after the Acquisition of a novel Oral Drug Delivery Technology

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.